4//SEC Filing
Gaslightwala Abizer 4
Accession 0001493152-25-028417
CIK 0001541157other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 9:56 PM ET
Size
14.8 KB
Accession
0001493152-25-028417
Insider Transaction Report
Form 4
Gaslightwala Abizer
Director
Transactions
- Purchase
Warrants to purchase American Depositary Shares ("ADRs")
2025-12-16+309,328→ 309,328 totalExercise: $0.39→ American Depositary Shares representing Ordinary Shares (309,328 underlying) - Purchase
Pre-Funded Warrants to purchase ADRs
2025-12-16$0.40/sh+309,328$124,999→ 309,328 totalExercise: $0.00→ American Depositary Shares representing Ordinary Shares (309,328 underlying) - Purchase
Warrants to purchase ADRs
2025-12-16+773,323→ 773,323 totalExercise: $0.39→ American Depositary Shares representing Ordinary Shares (773,323 underlying) - Purchase
Pre-Funded Warrants to purchase ADRs
2025-12-16$0.40/sh+773,323$312,500→ 773,323 totalExercise: $0.00→ American Depositary Shares representing Ordinary Shares (773,323 underlying)
Footnotes (7)
- [F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
- [F2]On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
- [F3]The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
- [F4]The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
- [F5]On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants").
- [F6]The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
- [F7]Conversion Exercise Price of Security is $0.00001
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0002049375
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 9:56 PM ET
- Size
- 14.8 KB